These findings reveal a novel mechanism underlying RT resistance in NSCLC and suggest that targeting NAT10 or its downstream pathways may provide a promising therapeutic strategy to overcome RT resistance in clinical settings. This evidence concerns the gene NAT10 and non-small cell lung carcinoma.